This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
Typos prompt Vyvanse product alert
Previous Pharma suppliers cop early hit from Trump trade war
Next MedAdvisor considering options to shore up revenue
Related Posts
Vyvanse supply issues ease
Supply issues impacting ADHD medication Vyvanse are set to return to normal by the end of the month Takeda Pharmaceuticals Australia is reporting that shortages of Vyvanse (lisdexamfetamine dimesilate) are easing, with supply of the 30mg and 50mg products deemed to have been “resolved”. However, the company advised the Therapeutic…
Further Vyvanse shortages forecast
Takeda Pharmaceuticals Australia warns that a fourth strength of its ADHD medication, Vyvanse, will be in short supply Worldwide shortages of Takeda’s Vyvanse (lisdexamfetamine dimesilate) products are expected to continue until late April, as a result of manufacturing issues, the company says. In an update issued by the Therapeutic…
Mixed news on Vyvanse shortage
There has been good, and bad, news about the ongoing shortage of the ADHD treatment The Therapeutic Goods Administration (TGA) has an update informing of mixed news about ongoing shortages of Vyvanse (lisdexamfetamine dimesilate) capsules, with a resolution achieved for one strength of the drug, while the shortage of another…